vTv Therapeutics is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. Its lead product candidate, cadisegliatin (TTP399), is a novel, small-molecule, liver-selective glucokinase activator being evaluated in a Phase 3 clinical trial as an adjunctive therapy to insulin for type 1 diabetes. The company is also advancing a Phase 2 trial for cadisegliatin in type 2 diabetes in the Middle East region in partnership with G42 Investments. Additionally, vTv Therapeutics holds a global license for its PDE4 inhibitor, HPP737, with Newsoara BioPharma Co., Ltd. The company collaborates with academic partners and other pharmaceutical organizations to advance its pipeline of drug candidates.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage vtvtherapeutics.com
Sector Healthcare IR page ir.vtvtherapeutics.com
Tags
diabetes, glucokinase activators, type 1 diabetes, type 2 diabetes, oral therapies, metabolic diseases, inflammatory diseases, clinical-stage, small-molecule drugs, cadisegliatin, TTP399, HPP737, CATT1, SimpliciT-1, G42 Investments, Newsoara BioPharma Co. Ltd.
Press page —

Metrics

Valuation  
Market cap $ 121.476M
Market cap (USD) $ 121.476M
P/E -15.82
PEG —
P/BV 1.74
P/S 119.44
P/OCF -5.59
P/FCF -4.81
Dividend yield —
Turnover / mcap —
Returns  
ROE -70.4%
ROI -41.9%
ROIC -38.2%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -84.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 0 1.017M 0 2.018M 4.005M 6.414M 2.764M 12.434M 291K 634K 519K 1.549M
Net profit -26.974M -18.462M -20.25M -19.164M -12.987M -8.499M -13.044M -7.911M -16.144M -16.352M -27.498M -36.101M
Free cash flow -25.255M -25.307M -19.081M -16.043M -19.308M — -23.088M -26.861M -44.617M -48.296M -37.05M -30.812M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 39.99 13.72 11.5 0.66 0.99 1.86 1.7 2.64 6.01 4.83 6.81 —
Price performance 12m 1.92 0.19 16.42 -0.34 -0.47 0.09 -0.36 -0.56 0.24 -0.29 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 0.00 8M 0.00 5,000 158,000 57,000 173,000 102,000 62,000 —
↳ YoY growth -100.0% -100.0% +3,060.0% -63.9% +203.5% -41.0% -39.2%
↳ 5y CAGR +18.0% -53.5% +65.5%
Borrowings, current (USD) — — 216,000 144,000 84,000 256,000 — — — —
Lease liabilities (USD) — — — 941,000 831,000 676,000 492,000 338,000 169,000 0.00
Cash and deposits (USD) 51.5M 11.8M 1.68M 1.78M 5.75M 13.4M 12.1M 9.45M 36.7M 88.9M
Right-of-use assets (USD) — — — 543,000 482,000 402,000 349,000 244,000 125,000 —
Net debt (borrowings + leases - cash) (USD) — — -1.47M -692,000 -4.83M -12.5M — — — —
Cash flow detail
Operating cash flow (USD) -48.2M -44.6M -26.9M -23M -18M -19.3M -16M -19.1M -25.3M -25.3M
Purchases of property, plant and equipment (USD) -87,000 -57,000 -5,000 -70,000 0.00 0.00 -21,000 0.00 0.00 —
Change in receivables (cash effect) (USD) 69,000 -8M 8M -5,000 -153,000 101,000 -116,000 71,000 40,000 —
Change in payables (cash effect) (USD) 4.79M 2.45M -6.2M -618,000 -997,000 1.83M -856,000 2.93M -5.22M 1.53M
Interest paid (cash effect) (USD) -242,000 -2.06M -2.28M -1.3M -623,000 -11,000 -15,000 -14,000 -2,000 -6,000
Income taxes paid (cash effect) (USD) — — -1M -100,000 0.00 -115,000 -200,000 0.00 -100,000 0.00
Share-based compensation (USD) 2.64M 3.65M 2.68M 1.52M 1.01M 2.36M 1.27M 1.58M 2.76M 3.78M
Operating cash flow before change in receivables (USD) -48.3M -36.6M -34.9M -23M -17.8M -19.4M -15.9M -19.2M -25.3M —
Free cash flow (OCF - PPE - intangibles) (USD) -48.3M -44.6M -26.9M -23.1M -18M -19.3M -16M -19.1M -25.3M —
Income detail
Research and development expense (USD) 45M 39.6M 23M 15.1M 11M 13.3M 12.4M 13.6M 11.5M 17.9M
↳ 5y CAGR +0.7% -2.7% -16.6% -21.6% -20.8% -10.0% -5.2% +10.1%
Reported Feb 24, 2017 Feb 27, 2018 Feb 26, 2019 Feb 21, 2020 Mar 6, 2023 Mar 6, 2023 Mar 6, 2023 Mar 13, 2024 Mar 20, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026

PDF Version

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027

Randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems

Company hosted a Key Opinion Leader (KOL) event in October, highlighting cadisegliatin and its potential to address hypoglycemia in people with T1D

FDA granted Orphan Drug Designation to HPPD, the Company’s oral, first-in-class Nrf2/Bach1 modulator being investigated as a potential treatment for sickle cell disease

Strong balance sheet expected to fund operations well through Phase 3 CATT1 topline data readout

HIGH POINT, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

In October 2026, the Company announced completion of enrollment in its Phase 3 CATT1 trial and continues to expect topline results in mid 2027, and randomized the first participant in Hybrid CATT1, its Phase 2a study of cadisegliatin in individuals with T1D who use hybrid closed-loop insulin delivery systems. Based on its cash position as of September 30, 2026, vTv expects to have sufficient cash to fund operations well through the anticipated CATT1 topline data readout. Also in October 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to HPPD, the Company’s oral drug candidate being investigated as a potential treatment for sickle cell disease.

“Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “In October we also randomized the first participant in Hybrid CATT1, our Phase 2a study of cadisegliatin in people with T1D who use hybrid closed-loop insulin delivery systems. As the experts at our KOL event made clear, hypoglycemia and its broader impact on blood glucose control remain a persistent burden for people with T1D even with the most advanced insulin delivery technology, and cadisegliatin aims to address exactly that.”

“We also continue to make important progress in our broader portfolio of highly differentiated small molecule drug candidates. The FDA recently granted Orphan Drug Designation for HPPD, which has shown promising activity in preclinical models of sickle cell disease. This designation strengthens our ability to advance partnering discussions for this program and provides another opportunity to create value for shareholders.”

Recent Company Highlights

  • Phase 3 CATT1 Trial Enrollment Completed. In October 2026, the Company announced completion of enrollment in its Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D. A total of 166 participants were randomized to receive cadisegliatin 800 mg once daily, cadisegliatin 800 mg twice daily, or placebo over six months. The primary efficacy endpoint will assess the incidence of level 2 and level 3 hypoglycemic events. Topline results are expected in mid 2027.

  • **Initiation of Cadisegliatin Hybrid Closed-Loop Trial (Hybrid CATT1).**On October 27, 2026, the Company announced that the first participant had been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Phase 2a Hybrid CATT1 trial is a randomized, double-blind, crossover, multicenter study that will evaluate cadisegliatin in T1D participants using hybrid closed-loop insulin delivery systems to inform the design and operational aspects of future Phase 3 research in this population.

  • KOL Event on Cadisegliatin Program. On October 20, 2026, the Company hosted a virtual KOL event featuring T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego) and Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist and T1D advocate Alisa Weilerstein. The event focused on T1D, the significant unmet medical need of hypoglycemia, and the cadisegliatin Phase 3 clinical program. A replay of the event is available in the Investor Relations section of the Company’s website.

  • Oral Presentation at Breakthrough T1D Clinical & Research Congress 2026. On October 10, 2026, Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin delivery (AID) systems at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. The research, a quantitative online survey commissioned by vTv and conducted by dQ&A Market Research, Inc., examined 674 adults with T1D, of whom 429 were using AID systems. After accounting for overlap across burden dimensions and weighting for A1C, approximately 54% of adults with T1D using an AID system were estimated to experience at least one of four dimensions of hypoglycemia-related burden, reinforcing that hypoglycemia continues to shape daily glucose management despite advances in insulin delivery technology.

  • FDA Orphan Drug Designation for HPPD. On October 6, 2026, the FDA granted Orphan Drug Designation to HPPD (HPP8668), an oral, first-in-class Nrf2/Bach1 modulator being investigated as a treatment for sickle cell disease. Preclinical studies conducted at Augusta University using the Townes sickle cell disease mouse model showed that HPPD was orally active and well tolerated, increased fetal hemoglobin, and reduced oxidative stress and red blood cell sickling. The designation will support partnering discussions for HPPD as the Company continues to prioritize cadisegliatin in T1D.

Third Quarter 2026 Financial Results

  • Cash Position: Cash and cash equivalents as of September 30, 2026, were $77.2 million compared to $88.9 million as of December 31, 2025.

  • Research & Development (R&D) Expenses: R&D expenses were $7.5 million and $7.0 million for the three months ended September 30, 2026, and 2025, respectively. The increase was primarily driven by continued investment in the Phase 3 CATT1 trial.

  • General & Administrative (G&A) Expenses: G&A expenses were $4.9 million and $3.7 million for the three months ended September 30, 2026, and 2025, respectively. The increase was primarily driven by higher share-based compensation and payroll-related expenses.

  • Interest Income: Interest income for the three months ended September 30, 2026, and 2025, of $0.7 million and $0.4 million, respectively, was related to dividend income from the Company's money market accounts.

  • Net Loss: Net loss attributable to vTv shareholders for the three months ended September 30, 2026, was $11.6 million or $0.94 per basic and diluted share. Net loss attributable to vTv shareholders for the comparable period a year ago was $8.7 million or $1.08 per basic and diluted share.

Upcoming Events

9th Annual Evercore HealthCONx Conference Format: Fireside Presentation and 1x1 Investor Meetings Location: Coral Gables, FL Date: December 2, 2026

| vTv Therapeutics Inc. Condensed Consolidated Balance Sheets (in thousands) |

| |

| | September 30, 2026 | | December 31, 2025 |

| | (Unaudited) | | |

| Assets | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 77,164 | | | $ | 88,932 | |

| Prepaid expenses and other current assets | | 1,440 | | | | 961 | |

| Total current assets | | 78,604 | | | | 89,893 | |

| Other assets | | 3 | | | | 6 | |

| Total assets | $ | 78,607 | | | $ | 89,899 | |

| Liabilities and Stockholders’ Equity | | | |

| Current liabilities: | | | |

| Accounts payable and accrued expenses | $ | 7,024 | | | $ | 6,557 | |

| Warrant liability, related party | | — | | | | 84 | |

| Total current liabilities | | 7,024 | | | | 6,641 | |

| Contract liabilities | | 1,830 | | | | 18,669 | |

| Warrant liability | | 67 | | | | 152 | |

| Total liabilities | | 8,921 | | | | 25,462 | |

| Commitments and contingencies | | | |

| Stockholders’ equity: | | | |

| Class A Common Stock | | 40 | | | | 39 | |

| Class B Common Stock | | — | | | | — | |

| Additional paid-in capital | | 396,878 | | | | 391,090 | |

| Accumulated deficit | | (327,232 | ) | | | (326,692 | ) |

| Total stockholders’ equity | | 69,686 | | | | 64,437 | |

| Total liabilities and stockholders’ equity | $ | 78,607 | | | $ | 89,899 | |

| |

| vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| | (Unaudited) | | (Unaudited) |

| Revenue | $ | — | | | $ | — | | | $ | 36,839 | | | $ | — | |

| Operating expenses: | | | | | | | |

| Research and development | | 7,531 | | | | 7,020 | | | | 25,279 | | | | 13,953 | |

| General and administrative | | 4,895 | | | | 3,679 | | | | 14,653 | | | | 10,970 | |

| Total operating expenses | | 12,426 | | | | 10,699 | | | | 39,932 | | | | 24,923 | |

| Operating loss | | (12,426 | ) | | | (10,699 | ) | | | (3,093 | ) | | | (24,923 | ) |

| Interest income | | 734 | | | | 399 | | | | 2,384 | | | | 1,005 | |

| Interest expense | | — | | | | (5 | ) | | | — | | | | (5 | ) |

| Other income (expense), net | | 72 | | | | (40 | ) | | | 169 | | | | (19 | ) |

| Net loss before income taxes and noncontrolling interest | | (11,620 | ) | | | (10,345 | ) | | | (540 | ) | | | (23,942 | ) |

| Income tax provision | | — | | | | — | | | | — | | | | — | |

| Net loss before noncontrolling interest | | (11,620 | ) | | | (10,345 | ) | | | (540 | ) | | | (23,942 | ) |

| Less: net loss attributable to noncontrolling interest | | — | | | | (1,647 | ) | | | — | | | | (4,106 | ) |

| Net loss attributable to vTv Therapeutics Inc. | $ | (11,620 | ) | | $ | (8,698 | ) | | $ | (540 | ) | | $ | (19,836 | ) |

| Net loss attributable to vTv Therapeutics Inc. common shareholders | $ | (11,620 | ) | | $ | (8,698 | ) | | $ | (540 | ) | | $ | (19,836 | ) |

| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $ | (0.94 | ) | | $ | (1.08 | ) | | $ | (0.04 | ) | | $ | (2.80 | ) |

| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | | 12,423,917 | | | | 8,055,940 | | | | 12,414,224 | | | | 7,080,681 | |

| |

About the Phase 3 CATT1 Study Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1) (NCT06334133) is a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of cadisegliatin over six months in individuals with T1D 18 years or older who are on multiple daily insulin injections or continuous subcutaneous insulin infusion, along with continuous glucose monitoring. Participants were randomized to receive cadisegliatin 800 mg once daily, cadisegliatin 800 mg twice daily, or placebo. The primary efficacy endpoint will assess the incidence of level 2 and level 3 hypoglycemic events. Secondary endpoints include changes in hemoglobin A1c (HbA1c), time in target glucose range, and the incidence of diabetic ketoacidosis in cadisegliatin-treated participants compared with placebo. Additional information about the study is available at https://clinicaltrials.gov/study/NCT06334133.

About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small-molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In nonclinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and its safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About HPPD HPPD (HPP8668) is an investigational, oral, first-in-class Nrf2/Bach1 modulator being developed by vTv Therapeutics for the treatment of sickle cell disease. Preclinical studies in the Townes sickle cell disease mouse model have shown that HPPD induces fetal hemoglobin (HbF) in a time- and dose-dependent manner, with effects comparable to or exceeding hydroxyurea, the current standard HbF-inducing therapy. In addition to HbF induction, HPPD showed reductions in oxidative stress and sickled red blood cells, supporting its potential as a disease-modifying oral therapy with a differentiated mechanism of action. HPPD is under investigation, and safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.

Forward-Looking Statements This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the timing of initiation and conduct of the Phase 2a Hybrid CATT1 study, the sufficiency of our cash to fund operations through the anticipated Phase 3 CATT1 topline data readout, potential partnering of HPPD, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact John Fraunces LifeSci Advisors, LLC 917-355-2395 [email protected]

Media Contact Caren Begun TellMed Strategies 201-396-8551 [email protected]

Primary Logo

Investor Contact

email [email protected]

October 27, 2026

PDF Version

Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population

Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment of T1D

HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin’s potential in this growing segment of the T1D population and to inform additional clinical studies.

Automated insulin delivery (AID) systems, also called closed-loop or artificial pancreas systems, combine a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to adjust insulin delivery automatically. HCL systems, the most common type of AID, automate basal insulin adjustments but still require the user to, for example, manage insulin dosing for meals or periods of exercise.

“Although HCL systems have improved the lives of people living with T1D, the risk and associated fear of hypoglycemia remain a significant burden on their day-to-day lives,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “As we advance our cadisegliatin program, this study seeks to deepen our understanding of how cadisegliatin may help improve glycemic control and reduce the burden of hypoglycemia for people who use HCL insulin delivery systems.”

An estimated 2.1 million people in the United States live with T1D,i with up to 40% of people with T1D now using AID systems.ii, iii, iv Yet over 40% of people with T1D who use AID systems still do not achieve the target A1C of less than 7.0%.v

Earlier this month, vTv Therapeutics announced the completion of enrollment in its Phase 3 CATT1 study of cadisegliatin for T1D. Because the Phase 3 study only enrolled participants using insulin pens or insulin pumps in an open-loop fashion, this Phase 2a pilot study will provide complementary insights into cadisegliatin’s metabolic effects in individuals using AID systems and inform larger future clinical studies.

About the Phase 2a Hybrid CATT1 Pilot Study The Phase 2a Cadisegliatin as Adjunctive Therapy to Insulin in Participants with T1D Who Are Using HCL Systems (Hybrid CATT1) study is a double-blind, randomized, placebo-controlled, two-way crossover study assessing cadisegliatin as an adjunctive treatment to insulin in adults with T1D using HCL insulin delivery systems.

The multicenter study is expected to enroll approximately 40 adults with T1D who have used an HCL system for at least three months before screening. The primary objective is to evaluate the effect of cadisegliatin on continuous glucose monitoring (CGM)-based measures of glycemic control, including Time in Range (TIR), following six weeks of treatment. The study also includes standardized mixed-meal tolerance tests to evaluate the effects of cadisegliatin on postprandial glucose excursions.

October 10, 2026

PDF Version

New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems

HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that Chief Medical Officer Thomas Strack, M.D., Ph.D., presented research spotlighting hypoglycemia-related burdens among adults with T1D using automated insulin delivery (AID) systems at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. Cadisegliatin is a potential first-in-class, liver-selective glucokinase activator (GKA) being evaluated as an oral adjunctive therapy to insulin for the treatment of T1D.

“A Cumulative Population View of Hypoglycemia-Related Burdens in T1D Adults Using AID Systems," a quantitative online research initiative commissioned by vTv Therapeutics and conducted by dQ&A Market Research, Inc., examined the prevalence of clinically meaningful hypoglycemia-related burdens among 674 adults with T1D of whom 429 were using AID systems. Among adult AID system users, 24% reported experiencing frequent Level 2 hypoglycemia, defined as daily, almost daily, or a few moderate hypoglycemic events (<54 mg/dL) in a typical week. 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia, defined as never or rarely noticing or feeling the symptoms of hypoglycemia. Among those with A1C >7%, 49% strongly agreed that they often keep their blood glucose higher to avoid hypoglycemia or that they would target lower glucose levels if not for the risk of hypoglycemia.

Respondents were then segmented using a mutually exclusive framework across the above four hypoglycemia-related burden dimensions. After accounting for overlap across segments and weighting for A1C, approximately 54% of adults with T1D using an AID system were estimated to experience at least one of the four dimensions of hypoglycemia-related burden.

“These findings reinforce that, despite meaningful advances in insulin delivery technology, insulin has its limitations and hypoglycemia continues to shape daily glucose management for many people with type 1 diabetes,” said Paul Sekhri, Chairman, President, and Chief Executive Officer of vTv Therapeutics. “The fact that more than half of adults using AID systems still experience clinically meaningful hypoglycemia-related burdens underscores the need for additional treatment options that can work alongside insulin and existing technologies to help address this burden.”

"Our mission at dQ&A is to serve as the voice of people living with diabetes. These findings highlight the challenges that many people with T1D continue to experience with hypoglycemia, including those using technologies such as AID,” said Richard Wood, Chief Executive Officer of dQ&A Market Research, Inc. “We are excited by the prospect of new therapies that could complement existing technologies and further alleviate this burden to give people greater confidence and freedom in their everyday lives.”

About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small-molecule, glucokinase activator being investigated in the U.S. as a potential first-in-class adjunctive treatment for T1D. In nonclinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and its safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

About vTv Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral glucokinase activator being investigated in a U.S. Phase 3 study for the treatment of T1D. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn.

About dQ&A Market Research, Inc. Founded in 2009, dQ&A Market Research is a leading diabetes-focused research firm dedicated to understanding the real-world experiences of people living with diabetes and those who care for them. Through our proprietary panels of thousands of patients and caregivers across the United States, Canada, and Europe, we conduct ongoing surveys and in-depth qualitative and quantitative research that capture the evolving needs, preferences, and challenges of the diabetes community. Our team includes seasoned researchers, data scientists, and consultants, many with a personal connection to diabetes, focused on delivering impactful and unbiased insights to the diabetes industry, government organizations, and medical associations. For more information, please visit www.d-qa.com or email [email protected].

Forward-Looking Statements This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.

Investor Contact John Fraunces LifeSci Advisors, LLC [email protected]

Media Contact Caren Begun TellMed Strategies 201-396-8551 [email protected]

Primary Logo

Investor Contact

email [email protected]

Prompts

vTv Therapeutics Inc. (ticker VTVT), listed in United States.

ETFs Holding vTv Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 576 $ 10.189K Nov 16, 2026